Waters and BD Receive FDA Clearance for At-Home HPV Screening Kit

Waters Corporation and BD (Becton, Dickinson and Company) have announced that the FDA has cleared the BD Onclarity HPV Assay for at-home self-collection. This regulatory milestone marks a significant shift in cervical cancer screening, providing a more accessible and private option for individuals across the United States. The initiative specifically targets the 60% of cervical cancer cases that occur among those who do not undergo regular clinical screenings. Waters is actively establishing strategic partnerships to ensure nationwide distribution and seamless access to these diagnostic kits. Furthermore, the integration of this kit into automated lab workflows is expected to streamline testing processes and improve overall diagnostic efficiency. Investors view this development as a bullish signal for both WAT and BDX, as it opens a substantial new market segment in home-based diagnostics.